Literature DB >> 16723797

Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein.

Masahito Sakuma1, Shigefumi Fukui, Mashio Nakamura, Tohru Takahashi, Osamu Kitamukai, Takahiro Yazu, Norikazu Yamada, Masahiro Ota, Takao Kobayashi, Takeshi Nakano, Kunio Shirato.   

Abstract

BACKGROUND: The specific incidence of thrombotic pulmonary embolism (PE), tumor PE and tumor invasion into large veins according to tumor type and tumor site remains unclear. METHODS AND
RESULTS: A total of 65,181 cancer patients were identified from 98,736 postmortem examinations. Thrombotic PE occurred in 2.32% of all cancer patients and comprised 88.6% of the total number of all PE events. The incidence of thrombotic PE was high in those with adenocarcinoma, leukemia and large cell carcinoma, and was low in those with hepatic cell carcinoma. The incidence of PE was high when tumor was present in hematogenous tissue, lungs, ovaries, pancreas and the biliary system, and was low when tumor was present in the liver. The incidence of tumor PE was high with large cell carcinoma, hepatic cell carcinoma and adenocarcinoma, and was also high when tumor was present in the lungs, ovaries, kidneys and liver. There was a significant correlation between the incidence of tumor PE and the incidence of tumor invasion into large veins.
CONCLUSION: The incidence of thrombotic PE, tumor PE and tumor invasion into large veins varies significantly according to tumor histopathology and tumor site.

Entities:  

Mesh:

Year:  2006        PMID: 16723797     DOI: 10.1253/circj.70.744

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  15 in total

Review 1.  Pathophysiology, clinics and diagnostics of non-thrombotic pulmonary embolism.

Authors:  Martina Montagnana; Gianfranco Cervellin; Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Clinicopathological Characteristics of Cancer-Associated Venous Thromboembolism (CAT-VTE) from a Medicolegal Autopsy.

Authors:  Ayako Ro; Norimasa Kageyama; Toshiji Mukai
Journal:  Ann Vasc Dis       Date:  2022-06-25

3.  Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism.

Authors:  Hong Wang; Yuan Huang; Chun-Wei Xu; Li Lin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Pulmonary Tumor Embolism Due to Squamous Cell Carcinoma of the Uterine Cervix: A Case Report.

Authors:  Shohei Okazaki; Takanori Abe; Natsuko Takayanagi; Masanori Yasuda; Fumikazu Sakai; Kunihiko Kobayashi; Shingo Kato
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

5.  Pulmonary Venous Obstruction in Cancer Patients.

Authors:  Chuang-Chi Liaw; Hung Chang; Tsai-Sheng Yang; Ming-Sheng Wen
Journal:  J Oncol       Date:  2015-09-06       Impact factor: 4.375

6.  Fatal tumour pulmonary embolism.

Authors:  Salim Rashid Masoud; Coenraad Frederik Nicolaas Koegelenberg; Abraham Christoffel van Wyk; Brian William Allwood
Journal:  Respirol Case Rep       Date:  2016-12-05

7.  A 51-year-old man with chronic cough and left hilar prominence.

Authors:  Ismini Kourouni; Scott W Aesif; Stephen W Tamarkin; Michael Bolen; Edward Sivak; Ziad Shaman; Ila Tamaskar; Vaia Florou
Journal:  Breathe (Sheff)       Date:  2021-06

8.  A fatal case of acute pulmonary embolism caused by right ventricular masses of acute lymphoblastic lymphoma-leukemia in a 13 year old girl.

Authors:  Yu Mi Ko; Soo Hyun Lee; June Huh; Hong Hoe Koo; Ji Hyuk Yang
Journal:  Korean J Pediatr       Date:  2012-07-17

Review 9.  Pulmonary tumor embolism secondary to soft tissue and bone sarcomas: a case report and literature review.

Authors:  Nicholas Latchana; Vincent C Daniel; Robert W Gould; Raphael E Pollock
Journal:  World J Surg Oncol       Date:  2017-08-30       Impact factor: 2.754

10.  Arterial Embolism in Malignancy: The Role of Surgery.

Authors:  Patrick Harnarayan; Shariful Islam; Vijay Naraynsingh
Journal:  Ther Clin Risk Manag       Date:  2021-06-18       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.